{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033075","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.460125+00:00","generated_at":"2026-05-25T10:37:49.935270+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Tomas Kiselak resigns; Sujay Kango appointed to board and compensation committee","bullets":["Tomas Kiselak resigned from Dianthus Therapeutics board effective March 4, 2025; no disagreement cited.","Sujay Kango appointed as Class II director and member of Compensation Committee, effective March 4, 2025.","Kango receives initial option grant of 25,000 shares vesting over three years; cash compensation of $40,000/yr (board) and $6,000/yr (committee).","Kango will enter into a standard indemnification agreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033075","json":"https://secwatch.observer/filing/0000950170-25-033075.json","markdown":"https://secwatch.observer/filing/0000950170-25-033075.md","text":"https://secwatch.observer/filing/0000950170-25-033075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/dnth-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:37:49.935270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f125b6f816","claim":"Sujay Kango was appointed as Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f960bb8331","claim":"Tomas Kiselak resigned as Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025033075/0000950170-25-033075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}